Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression. (Q51155024)

31 March 2018

title

Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression. (English)

1 reference

31 March 2018

1 reference

Yoshihisa Umekita

1

1 reference

31 March 2018

Masakazu Souda

2

1 reference

31 March 2018

Yasuyo Ohi

3

1 reference

31 March 2018

Yoshiatsu Sagara

4

1 reference

31 March 2018

Yoshiaki Rai

5

1 reference

31 March 2018

Tetsuya Takahama

6

1 reference

31 March 2018

Hiroki Yoshida

7

1 reference

31 March 2018

publication date

1 August 2006

1 reference

31 March 2018

published in

Pathology International

1 reference

31 March 2018

volume

56

1 reference

31 March 2018

issue

8

1 reference

31 March 2018

page(s)

423-427

1 reference

31 March 2018

Oestrogen receptor beta: what it means for patients with breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Reduced expression of oestrogen receptor β in invasive breast cancer and its re‐expression using DNA methyl transferase inhibitors in a cell line model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Wild-type estrogen receptor beta expression in normal and neoplastic paraffin-embedded tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

Estrogen receptors and proliferation markers in primary and recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2006.01983.X

10.1111/J.1440-1827.2006.01983.X

21 January 2018

Identifiers

DOI

1 reference

31 March 2018

PubMed ID

16872435

1 reference

31 March 2018